THAR
Tharimmune, Inc.
Biotechnology
Market Cap$140M
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
THAR vs PRTA
Revenue, margins, valuation, and 5-year total return — side by side.
PRTA
Prothena Corporation plc
Biotechnology
Market Cap$567M
5Y Perf.-71.5%
THAR vs PRTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | THAR | PRTA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $140M | $567M |
| Revenue (TTM) | $0.00 | $58M |
| Net Income (TTM) | $-10M | $-151M |
| Gross Margin | — | -39.7% |
| Operating Margin | — | -210.6% |
| Forward P/E | — | 42.7x |
| Total Debt | $0.00 | $14M |
| Cash & Equiv. | $4M | $308M |
THAR vs PRTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
THAR
PRTA
| Stock | Jan 22 | Apr 26 | Return |
|---|---|---|---|
| Tharimmune, Inc. (THAR) | 100 | 0.2 | -99.8% |
| Prothena Corporatio… (PRTA) | 100 | 28.5 | -71.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: THAR vs PRTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: THAR leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Prothena Corporation plc is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
THAR
Tharimmune, Inc.
The Growth Play
THAR carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 91.2%
- -92.6% revenue growth vs PRTA's -92.8%
- 6.3% margin vs PRTA's -260.9%
Best for: growth exposure
PRTA
Prothena Corporation plc
The Income Pick
PRTA is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.96
- -73.0% 10Y total return vs THAR's -99.7%
- Lower volatility, beta 0.96, Low D/E 4.9%, current ratio 7.72x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | THAR | -92.6% revenue growth vs PRTA's -92.8% |
| Quality / Margins | THAR | 6.3% margin vs PRTA's -260.9% |
| Stability / Safety | PRTA | Beta 0.96 vs THAR's 1.28 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | THAR | +129.9% vs PRTA's +44.4% |
| Efficiency (ROA) | PRTA | -42.3% ROA vs THAR's -264.4% |
THAR vs PRTA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
THAR vs PRTA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRTALAGGINGTHAR
THARTharimmune, Inc.
0leads
PRTAProthena Corporation …
5leads
6 Total Categories
CATEGORYLEADERvs THARMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRTA1/1
Valuation MetricsMultiples, price ratios, and targets
PRTA2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRTA4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
PRTA5/6
Risk & VolatilityBeta, volatility, and downside exposure
PRTA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PRTA and THAR operate at a comparable scale, with $58M and $0 in trailing revenue.
| Metric | THARTharimmune, Inc. | PRTAProthena Corporat… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $58M |
| EBITDAEarnings before interest/tax | -$10M | -$121M |
| Net IncomeAfter-tax profit | -$10M | -$151M |
| Free Cash FlowCash after capex | -$9M | -$85M |
| Gross MarginGross profit ÷ Revenue | — | -39.7% |
| Operating MarginEBIT ÷ Revenue | — | -2.1% |
| Net MarginNet income ÷ Revenue | — | -2.6% |
| FCF MarginFCF ÷ Revenue | — | -147.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +86.1% | +153.6% |
PRTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
PRTA leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | THARTharimmune, Inc. | PRTAProthena Corporat… |
|---|---|---|
| Market CapShares × price | $140M | $567M |
| Enterprise ValueMkt cap + debt − cash | $136M | $273M |
| Trailing P/EPrice ÷ TTM EPS | -0.38x | -2.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 42.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 58.54x |
| Price / BookPrice ÷ Book value/share | 3.51x | 2.02x |
| Price / FCFMarket cap ÷ FCF | — | — |
PRTA leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
PRTA leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
PRTA delivers a -49.9% return on equity — every $100 of shareholder capital generates $-50 in annual profit, vs $-6 for THAR.
| Metric | THARTharimmune, Inc. | PRTAProthena Corporat… |
|---|---|---|
| ROE (TTM)Return on equity | -5.9% | -49.9% |
| ROA (TTM)Return on assets | -2.6% | -42.3% |
| ROICReturn on invested capital | — | -21.0% |
| ROCEReturn on capital employed | -2.4% | -47.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | — | 0.05x |
| Net DebtTotal debt minus cash | -$4M | -$294M |
| Cash & Equiv.Liquid assets | $4M | $308M |
| Total DebtShort + long-term debt | $0 | $14M |
| Interest CoverageEBIT ÷ Interest expense | -411.14x | — |
PRTA leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
PRTA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRTA five years ago would be worth $4,277 today (with dividends reinvested), compared to $27 for THAR. Over the past 12 months, THAR leads with a +129.9% total return vs PRTA's +44.4%. The 3-year compound annual growth rate (CAGR) favors PRTA at -48.5% vs THAR's -72.0% — a key indicator of consistent wealth creation.
| Metric | THARTharimmune, Inc. | PRTAProthena Corporat… |
|---|---|---|
| YTD ReturnYear-to-date | +4.7% | +14.5% |
| 1-Year ReturnPast 12 months | +129.9% | +44.4% |
| 3-Year ReturnCumulative with dividends | -97.8% | -86.3% |
| 5-Year ReturnCumulative with dividends | -99.7% | -57.2% |
| 10-Year ReturnCumulative with dividends | -99.7% | -73.0% |
| CAGR (3Y)Annualised 3-year return | -72.0% | -48.5% |
PRTA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
PRTA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRTA is the less volatile stock with a 0.96 beta — it tends to amplify market swings less than THAR's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRTA currently trades 90.1% from its 52-week high vs THAR's 39.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | THARTharimmune, Inc. | PRTAProthena Corporat… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.28x | 0.96x |
| 52-Week HighHighest price in past year | $9.08 | $11.69 |
| 52-Week LowLowest price in past year | $1.08 | $4.32 |
| % of 52W HighCurrent price vs 52-week peak | +39.0% | +90.1% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 60.3 |
| Avg Volume (50D)Average daily shares traded | 401K | 474K |
PRTA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates THAR as "Hold" and PRTA as "Buy".
| Metric | THARTharimmune, Inc. | PRTAProthena Corporat… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | — | $19.00 |
| # AnalystsCovering analysts | 1 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRTA leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallProthena Corporation plc (PRTA)Leads 5 of 6 categories
Loading custom metrics...
THAR vs PRTA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is THAR or PRTA a better buy right now?
Analysts rate Prothena Corporation plc (PRTA) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — THAR or PRTA?
Over the past 5 years, Prothena Corporation plc (PRTA) delivered a total return of -57.
2%, compared to -99. 7% for Tharimmune, Inc. (THAR). Over 10 years, the gap is even starker: PRTA returned -73. 0% versus THAR's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — THAR or PRTA?
By beta (market sensitivity over 5 years), Prothena Corporation plc (PRTA) is the lower-risk stock at 0.
96β versus Tharimmune, Inc. 's 1. 28β — meaning THAR is approximately 33% more volatile than PRTA relative to the S&P 500.
04Which is growing faster — THAR or PRTA?
On earnings-per-share growth, the picture is similar: Tharimmune, Inc.
grew EPS 91. 2% year-over-year, compared to -99. 6% for Prothena Corporation plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — THAR or PRTA?
Tharimmune, Inc.
(THAR) is the more profitable company, earning 0. 0% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THAR leads at 0. 0% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PRTA leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — THAR or PRTA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is THAR or PRTA better for a retirement portfolio?
For long-horizon retirement investors, Prothena Corporation plc (PRTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
96)). Both have compounded well over 10 years (PRTA: -73. 0%, THAR: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between THAR and PRTA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.